IP Verse

Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb)

Patent No. EP4014976 (titled "Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb)") was filed by Idorsia Pharmaceuticals on Feb 26, 2018. The application was issued on Sep 4, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ELKINGTON AND FIFEMay 29, 2025ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4014976

IDORSIA PHARMACEUTICALS
Application Number
EP21202979A
Filing Date
Feb 26, 2018
Status
Granted And Under Opposition
Aug 2, 2024
Publication Date
Sep 4, 2024
External Links
Slate, Register , Google Patents